B-myb promoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells

Journal of Virology

Volumn 73, Issue 9, 1999, Pages 7556-7564

  Chung, Richard Y ^a   Saeki, Yoshinaga ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION; VIRULENCE;

EID: 0032865620     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.9.7556-7564.1999     Document Type: Article

References (53)

1. Bennett, J. D., P. G. Farlie, and R. J. Watson. 1996. E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts. Oncogene 13:1073-1082.
2. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
3. Bobo, R. H., D. W. Laske, A. Akbasak, P. F. Morrison, R. L. Dedrick, and E. H. Oldfield. 1994. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91:2076-2080.
4. Boviatsis, E. J., M. Chase, M. X. Wei, T. Tamiya, R. K. Hurford, Jr., N. W. Kowall, R. I. Tepper, X. O. Breakefield, and E. A. Chiocca. 1994. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther. 5:183-191.
5. Boviatsis, E. J., J. S. Park, M. Sena-Esteves, C. M. Kramm, M. Chase, J. T. Efird, M. X. Wei, X. O. Breakefield, and E. A. Chiocca. 1994. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54:5745-5751.
6. Boviatsis, E. J., J. M. Scharf, M. Chase, K. Harrington, N. W. Kowall, X. O. Breakefield, and E. A. Chiocca. 1994. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1:323-331.
7. Centifanto-Fitzgerald, Y. M., T. Yamaguchi, H. E. Kaufman, M. Tognon, and B. Roizman. 1982. Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA. J. Exp. Med. 155:475-489.
8. Chambers, R., G. Y. Gillespie, L. Soroceanu, S. Andreansky, S. Chatterjee, J. Chou, B. Roizman, and R. J. Whitley. 1995. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92: 1411-1415.
9. Chase, M., R. Y. Chung, and E. A. Chiocca. 1998. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16:444-448.
10. - mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci USA 92:10516-10520.
11. Chou, J., E. R. Kern, R. J. Whitley, and B. Roizman. 1990. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250:1262-1266.
12. 134.5 gene of herpes simplex virus. J. Virol. 68:8304-8311.
13. 134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA 89:3266-3270.
14. Chung, R. Y., and E. A. Chiocca. 1998. Gene therapy for tumors of the central nervous system. Surg. Oncol. Clin. N. Am. 7:589-602.
15. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
16. Cosentino, G. P., S. Venkatesan, F. C. Serluca, S. R. Green, M. B. Mathews, and N. Sonenberg. 1995. Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo. Proc. Natl. Acad. Sci. USA 92:9445-9449.
17. Gale, M., Jr., C. M. Blakely, B. Kwieciszewski, S.-L. Tan, M. Dossett, N. M. Tang, M. J. Korth, S. J. Polyak, D. R. Gretch, and M. G. Katze. 1998. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18:5208-5218.
18. Goldstein, D. J., and S. K. Weller. 1988. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:196-205.
19. Goldstein, D. J., and S. K. Weller. 1988. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J. Virol. 62:2970-2977.
20. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:9479-9490.
21. He, J., J. R. Allen, V. P. Collins, M. J. Allalunis-Turner, R. Godbout, R. S. Day III, and C. D. James. 1994. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:5804-5807.
22. Huang, H. S., M. Nagane, C. K. Klingbeil, H. Lin, R. Nishikawa, X. D. Ji, C. M. Huang, G. N. Gill, H. S. Wiley, and W. K. Cavenee. 1997. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272: 2927-2935.
23. Katze, M. G. 1995. Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol. 3:75-78.
24. Kesari, S., T. M. Lasner, K. R. Balsara, B. P. Randazzo, V. M. Lee, J. Q. Trojanowski, and N. W. Fraser. 1998. A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. 79:525-536.
25. Kesari, S., V. M. Lee, S. M. Brown, J. Q. Trojanowski, and N. W. Fraser. 1996. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J. Neurosci. 16:5644-5653.
26. Kramm, C. M., M. Chase, U. Herrlinger, A. Jacobs, P. A. Pechan, N. G. Rainov, M. Sena-Esteves, M. Aghi, F. H. Barnett, E. A. Chiocca, and X. O. Breakefield. 1997. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:2057-2068.
27. Lam, E. W., J. D. Bennett, and R. J. Watson. 1995. Cell-cycle regulation of human B-myb transcription. Gene 160:277-281.
28. Lam, E. W., and R. J. Watson. 1993. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:2705-2713.
29. Markert, J. M., A. Malick, D. M. Coen, and R. L. Martuza. 1993. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603.
30. - mutant of herpes simplex virus 1. J. Virol. 71:5560-5569.
31. Martuza, R. L. Personal communication.
32. Martuza, R. L., A. Malick, J. M. Markert, K. L. Ruffner, and D. M. Coen. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
33. McGeoch, D. J., C. Cunningham, G. McIntyre, and A. Dolan. 1991. Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2. J. Gen. Virol. 72:3057-3075.
34. Mineta, T., S. D. Rabkin, and R. L. Martuza. 1994. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54:3963-3966.
35. Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter, and K. L. Martuza. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:938-943.
36. Miyatake, S., A. Iyer, R. L. Martuza, and S. D. Rabkin. 1997. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71: 5124-5132.
37. Mohr, I., and Y. Gluzman. 1996. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 15:4759-4766.
38. Moriuchi, S., T. Oligino, D. Krisky, P. Marconi, D. Fink, J. Cohen, and J. C. Glorioso. 1998. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res. 58:5731-5737.
39. Morse, L. S., L. Pereira, B. Roizman, and P. A. Schaffer. 1978. Anatomy of herpes simplex virus (HSV) DNA. X. Mapping of viral genes by analysis of polypeptides and functions specified by HSV-1 X HSV-2 recombinants. J. Virol. 26:389-410.
40. Nagane, M., F. Coufal, H. Lin, O. Bogler, W. K. Cavenee, and H. J. Huang. 1996. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:5079-5086.
41. Nishikawa, R., X. D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavenee, and H. J. Huang. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 91:7727-7731.
42. Parr, M. J., Y. Manome, T. Tanaka, P. Wen, D. W. Kufe, W. G. Kaelin, Jr., and H. A. Fine. 1997. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3:1145-1149.
43. Puumalainen, A. M., M. Vapalahti, R. S. Agrawal, M. Kossila, J. Laukkanen, P. Lehtolainen, H. Viita, L. Paljarvi, R. Vanninen, and S. Yla-Herttuala. 1998. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9:1769-1774.
44. Pyles, R. B., and R. L. Thompson. 1994. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Virol. 68:4963-4972.
45. Pyles, R. B., R. E. Warnick, C. L. Chalk, B. E. Szanti, and L. M. Parysek. 1997. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8:533-544.
46. Qureshi, N., and E. A. Chiocca. Unpublished data.
47. Ram, Z., K. W. Culver, E. M. Oshiro, J. J. Viola, H. L. DeVroom, E. Otto, Z. Long, Y. Chiang, G. J. McGarrity, L. M. Muul, D. Katz, R. M. Blaese, and E. H. Oldfield. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1354-1361.
48. Schang, L. M., J. Phillips, and P. A. Schaffer. 1998. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72:5626-5637.
49. Schwarzchild, M. A., R. L. Cole, and S. E. Hyman. 1997. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. J. Neurosci. 17:3455-3466.
50. Sharp, T. V., M. Schwemmle, I. Jeffrey, K. Laing, H. Mellor, C. G. Proud, K. Hilse, and M. J. Clemens. 1993. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res. 21: 4483-4490.
51. Toda, M., S. D. Rabkin, and R. L. Martuza. 1998. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9:2177-2185.
52. Ueki, K., Y. Ono, J. W. Henson, J. T. Efird, A. von Deimling, and D. N. Louis. 1996. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56:1:50-153.
53. Wei, M. X., T. Tamiya, M. Chase, E. J. Boviatsis, T. K. Chang, N. W. Kowall, F. H. Hochberg, D. J. Waxman, X. O. Breakefield, and E. A. Chiocca. 1994. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5:969-978.